A Phase 1b/2 Open-Label, Dose Escalation and Expansion Study of Orally Administered VRx-3996 and Valganciclovir in Subjects with Epstein-Barr Virus-Associated Lymphoid Malignancies

Primary Objective

Determine the safety and tolerability of VRx-3996/valganciclovir. Evaluate the impact of parameters of HIV infection (e.g., CD4 cell counts, HIVqPCR) on safety and efficacy. And Evaluate the impact of VRx-3996/valganciclovir on replication of non-Alpha herpesviruses.

This Study is
No Longer Enrolling

Details
Age

Adult

Type of Study

Treatment

Locations

Lone Tree Medical Center
University of Colorado Hospital

Study ID

Protocol Number: 17-2074

More information available at ClinicalTrials.gov: NCT03397706

Categories

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers